

Cheilonda Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8636524/publications.pdf>

Version: 2024-02-01

18
papers

936
citations

687335

13
h-index

888047

17
g-index

18
all docs

18
docs citations

18
times ranked

1142
citing authors

#	ARTICLE	IF	CITATIONS
1	A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. <i>Rheumatology</i> , 2017, 56, 999-1007.	1.9	166
2	Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1771-1776.	3.4	130
3	Management of Myositis-Related Interstitial Lung Disease. <i>Chest</i> , 2016, 150, 1118-1128.	0.8	106
4	Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. <i>Lung</i> , 2016, 194, 733-737.	3.3	95
5	Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. <i>Chest</i> , 2019, 156, 896-906.	0.8	77
6	Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. <i>Neurology</i> , 2018, 90, e2068-e2076.	1.1	76
7	Association of Cross-Reactive Antibodies Targeting Peptidyl-Arginine Deiminase 3 and 4 with Rheumatoid Arthritis-Associated Interstitial Lung Disease. <i>PLoS ONE</i> , 2014, 9, e98794.	2.5	58
8	Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2017, 29, 254-259.	4.3	54
9	“Hiker’s feet”: a novel cutaneous finding in the inflammatory myopathies. <i>Clinical Rheumatology</i> , 2017, 36, 1683-1686.	2.2	36
10	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. <i>Neurology</i> , 2019, 92, e1416-e1426.	1.1	36
11	More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. <i>Neurology</i> , 2019, 93, e1768-e1777.	1.1	35
12	Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. <i>Respiratory Medicine</i> , 2017, 130, 52-54.	2.9	22
13	Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis. <i>PLoS ONE</i> , 2016, 11, e0153024.	2.5	19
14	The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2019, 150, 63-65.	2.9	13
15	Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometry. <i>Rheumatology</i> , 2022, 61, 2792-2804.	1.9	7
16	Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 858-861.	0.8	5
17	MUC5B Promoter Variant Is Not Associated With Myositis-Related Interstitial Lung Disease. <i>Chest</i> , 2012, 142, 422A.	0.8	1
18	The Genetics of Pulmonary Fibrosis. , 2014, , 207-220.		0